Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
about
Integrin and GPCR Crosstalk in the Regulation of ASM Contraction Signaling in AsthmaRegular treatment with salmeterol for chronic asthma: serious adverse eventsLong-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaDeterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down".Notes on testing equality and interval estimation in Poisson frequency data under a three-treatment three-period crossover trial.Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation.Interactions between corticosteroids and beta agonists.Long-acting inhaled beta(2)-agonist therapy in asthma.Asthma and allergy: a worldwide problem of meanings and management?Beta-agonists and asthma: too much of a good thing?Randomised trial of an inhaled beta2 agonist, inhaled corticosteroid and their combination in the treatment of asthmaAsthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.Mast cells in airway diseases and interstitial lung diseaseBidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle β2 Adrenoceptors.Beta-arrestins specifically constrain beta2-adrenergic receptor signaling and function in airway smooth muscleRisk versus benefit considerations for the beta(2)-agonists.Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control.Safety of long-acting beta2-agonists in the treatment of asthma.Regulation of T cells in airway disease by beta-agonist.Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis.Mast cells in asthma--state of the art.Daily exhaled nitric oxide measurements and asthma exacerbations in children.Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma modelThe effects of acute and chronic nadolol treatment on β2AR signaling in HEK293 cells.Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells.Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma.Beta2-agonist tolerance and exercise-induced bronchospasm.Adherence to asthma self-management plans with inhaled corticosteroid and oral prednisone: A descriptive analysis.Effect of combining salmeterol and fluticasone on the progression of airway remodeling.Beta2-agonist eutomers: a rational option for the treatment of asthma?Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
P2860
Q21296663-E90CE938-D607-4F90-AAC5-08007A2FEFD4Q24241960-4DB41A07-FBDC-4862-9AF4-90101273DB76Q24246441-FCBC11E9-6C14-4C3C-A764-751C04722619Q24247926-DF8A01E3-A9F1-466C-9DB1-3FF552E3C0F7Q30447195-ED01C4D0-D030-49B0-B9EE-408323BF2884Q30736948-D7CCD5A5-F3EB-4D81-AD40-2A9D6AF4CD02Q33860283-683B06DE-A502-424F-9CB9-F991EA10FBDBQ33944522-F2DB6E83-081A-4F86-86BB-FCD4CD61F9D0Q34392656-0F1A3044-0A5D-4ACE-8B26-C3655CEF6ECAQ34744026-7C79B2A7-8847-4AAF-B6B3-C1873C670220Q35202472-BEBA58FA-3D78-47CB-830B-4FCBD7F9BB6DQ35533126-1C957C4B-7321-49A8-8465-AB5FD9AB7C39Q35534065-B1E82DC7-E52C-40EF-A432-4B40C9CB81D4Q35627925-A3CABB73-2767-4E37-9B94-AEB01F9FB522Q36260500-1E096DEC-F6D9-4AE2-BE39-2EB211A5176BQ36389176-9CEB5FA5-6B66-4654-A104-16263E26887BQ36445260-C70C9799-F4E3-4A0B-8FC9-05303396B4F4Q36582709-EB604FCB-DAFE-48EE-B119-4F70355A5A50Q37274731-733E4F81-AE8A-4079-9648-AD39F6EA66F6Q37362572-28639850-6BA2-4E1E-B74D-D99C43E4A13BQ37762035-3F877FDF-900D-418C-8C93-9CB939930364Q38219526-CF24A8FD-A001-4273-97F8-29D277669D93Q38633155-066552C6-5043-4F47-BFE6-964FACCE9995Q39697472-DF91DF3C-D109-4F99-89E1-111E89448B81Q41928013-18CDD13A-159D-421A-99A7-E1B723285086Q42482442-DC6F5C2A-71BB-4017-9E9E-9E899EA845A7Q42741835-B4B3BBBF-CD51-43EB-B5A7-E0321109D304Q43660405-3805A0A3-3E61-4B1A-A336-5E3CF83C6EDCQ43961067-DA1124FE-6697-4895-B145-DF2D00CC020EQ43977353-0F20ED8A-5D8F-44E2-8296-87806014025FQ44179176-A8287393-3713-4DFB-B6B7-BA262C1D2FD2Q44726379-33AE259C-C5FA-4818-87F6-510472A4AF35Q46829177-A1208356-B102-412D-AE25-86864523C6FA
P2860
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
@ast
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
@en
type
label
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
@ast
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
@en
prefLabel
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
@ast
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
@en
P2093
P2860
P356
P1433
P1476
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol
@en
P2093
C M Ramsay
D Boothman-Burrell
D R Taylor
E M Flannery
G Richards
K Laubscher
V Linscott
P2860
P304
P356
10.1136/THX.53.9.744
P407
P577
1998-09-01T00:00:00Z